Political Views And Vaccine Refusal Rates An Increasing Concern For Policymakers And Public Health Officials 13/07/2018 Tatum Anderson Or they should be. That’s the conclusion of a recent study published in the medical journal Vaccine. The study focused on political views of parents in the state of California, who had chosen not to vaccinate their nursery-school aged children. And it tracked the number of parents who had filed personal belief exemptions (PBEs), applications for permission to avoid vaccinations over a 5-year period to 2015. A disproportionate number of parents filing such forms were from Republican or conservative neighbourhoods, according to researcher Kevin A Estep, from the health administration and policy program at the university. Continue reading -> First Results Of Pharma-Led Initiative To Increase Access To Treatments 29/06/2018 Catherine Saez Early results of a biopharmaceutical companies-based initiative to encourage access to treatment in developing countries shows a focus on cancer, diabetes, and cardiovascular disease, through 62 programmes. The report, conducted by an independent observatory, provides key findings on several areas, including local priorities, and social inequity. Continue reading -> CDC Director Redfield: Long-Term Investment In Global Health Security Most Critical 14/06/2018 William New WASHINGTON, DC -- Recently named director of the US Centers for Disease Control and Prevention (CDC) Robert Redfield told a gathering of global health experts this week that the most critical investment that can be made is in global health security, with the recent fast response to the Ebola outbreak in the Democratic Republic of the Congo setting the example. Continue reading -> Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> UAEM Students Launch Campaign To Drop Publicly Funded Patent Claim On Cancer Drug In India 16/03/2018 William New The Universities Allied for Essential Medicines (UAEM) this week launched a campaign to ask the University of California to drop its pursuit of a patent on the prostrate cancer drug Xtandi in India in order to make it affordable for patients. Xtandi sells at "exorbitant" rates in the United States, they said, a seeming violation of the licensing guidelines of the publicly funded University of California system which guarantees an "appropriate" return on taxpayer investments. Continue reading -> CARB-X Announces 2018 Round Of Funding For Antibacterial Research 23/02/2018 William New CARB-X , a global private-public partnership for research on antimicrobial resistance, this week announced its 2018 rounds of funding for research on "antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria." Continue reading -> “We Count On The US To Maintain Its Commitment” – Global Fund On US Budget Cut 22/02/2018 William New Some international organisations are having to gear up to address proposed cuts to their budgets announced this month by the United States, in many cases the major funder. Geneva-based health agencies this week responded that they are counting on the US not to make significant cuts. Continue reading -> Indian Pharma Industry Disputes US Industry IP Index 15/02/2018 William New The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving". Continue reading -> Posts navigation Older postsNewer posts
First Results Of Pharma-Led Initiative To Increase Access To Treatments 29/06/2018 Catherine Saez Early results of a biopharmaceutical companies-based initiative to encourage access to treatment in developing countries shows a focus on cancer, diabetes, and cardiovascular disease, through 62 programmes. The report, conducted by an independent observatory, provides key findings on several areas, including local priorities, and social inequity. Continue reading -> CDC Director Redfield: Long-Term Investment In Global Health Security Most Critical 14/06/2018 William New WASHINGTON, DC -- Recently named director of the US Centers for Disease Control and Prevention (CDC) Robert Redfield told a gathering of global health experts this week that the most critical investment that can be made is in global health security, with the recent fast response to the Ebola outbreak in the Democratic Republic of the Congo setting the example. Continue reading -> Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> UAEM Students Launch Campaign To Drop Publicly Funded Patent Claim On Cancer Drug In India 16/03/2018 William New The Universities Allied for Essential Medicines (UAEM) this week launched a campaign to ask the University of California to drop its pursuit of a patent on the prostrate cancer drug Xtandi in India in order to make it affordable for patients. Xtandi sells at "exorbitant" rates in the United States, they said, a seeming violation of the licensing guidelines of the publicly funded University of California system which guarantees an "appropriate" return on taxpayer investments. Continue reading -> CARB-X Announces 2018 Round Of Funding For Antibacterial Research 23/02/2018 William New CARB-X , a global private-public partnership for research on antimicrobial resistance, this week announced its 2018 rounds of funding for research on "antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria." Continue reading -> “We Count On The US To Maintain Its Commitment” – Global Fund On US Budget Cut 22/02/2018 William New Some international organisations are having to gear up to address proposed cuts to their budgets announced this month by the United States, in many cases the major funder. Geneva-based health agencies this week responded that they are counting on the US not to make significant cuts. Continue reading -> Indian Pharma Industry Disputes US Industry IP Index 15/02/2018 William New The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving". Continue reading -> Posts navigation Older postsNewer posts
CDC Director Redfield: Long-Term Investment In Global Health Security Most Critical 14/06/2018 William New WASHINGTON, DC -- Recently named director of the US Centers for Disease Control and Prevention (CDC) Robert Redfield told a gathering of global health experts this week that the most critical investment that can be made is in global health security, with the recent fast response to the Ebola outbreak in the Democratic Republic of the Congo setting the example. Continue reading -> Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> UAEM Students Launch Campaign To Drop Publicly Funded Patent Claim On Cancer Drug In India 16/03/2018 William New The Universities Allied for Essential Medicines (UAEM) this week launched a campaign to ask the University of California to drop its pursuit of a patent on the prostrate cancer drug Xtandi in India in order to make it affordable for patients. Xtandi sells at "exorbitant" rates in the United States, they said, a seeming violation of the licensing guidelines of the publicly funded University of California system which guarantees an "appropriate" return on taxpayer investments. Continue reading -> CARB-X Announces 2018 Round Of Funding For Antibacterial Research 23/02/2018 William New CARB-X , a global private-public partnership for research on antimicrobial resistance, this week announced its 2018 rounds of funding for research on "antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria." Continue reading -> “We Count On The US To Maintain Its Commitment” – Global Fund On US Budget Cut 22/02/2018 William New Some international organisations are having to gear up to address proposed cuts to their budgets announced this month by the United States, in many cases the major funder. Geneva-based health agencies this week responded that they are counting on the US not to make significant cuts. Continue reading -> Indian Pharma Industry Disputes US Industry IP Index 15/02/2018 William New The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving". Continue reading -> Posts navigation Older postsNewer posts
Trump Declares Intent To Stop Pharma Companies From ‘Gaming’ Patent System 11/05/2018 William New US President Trump today declared in a White House speech his intent to "take steps" to lower drug prices by stopping "gaming of regulatory and patent processes by drug makers to unfairly protect monopolies," as well as increasing price transparency and promoting biosimilars and generics. But to do this, his administration will take on what it sees as "freeloading" on US innovation by foreign governments, and addressing "unfair" intellectual property and market access policies in trade agreements. Continue reading -> USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> UAEM Students Launch Campaign To Drop Publicly Funded Patent Claim On Cancer Drug In India 16/03/2018 William New The Universities Allied for Essential Medicines (UAEM) this week launched a campaign to ask the University of California to drop its pursuit of a patent on the prostrate cancer drug Xtandi in India in order to make it affordable for patients. Xtandi sells at "exorbitant" rates in the United States, they said, a seeming violation of the licensing guidelines of the publicly funded University of California system which guarantees an "appropriate" return on taxpayer investments. Continue reading -> CARB-X Announces 2018 Round Of Funding For Antibacterial Research 23/02/2018 William New CARB-X , a global private-public partnership for research on antimicrobial resistance, this week announced its 2018 rounds of funding for research on "antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria." Continue reading -> “We Count On The US To Maintain Its Commitment” – Global Fund On US Budget Cut 22/02/2018 William New Some international organisations are having to gear up to address proposed cuts to their budgets announced this month by the United States, in many cases the major funder. Geneva-based health agencies this week responded that they are counting on the US not to make significant cuts. Continue reading -> Indian Pharma Industry Disputes US Industry IP Index 15/02/2018 William New The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving". Continue reading -> Posts navigation Older postsNewer posts
USTR IP Report Sparks Outcry Among Health Advocates 27/04/2018 William New The annual Special 301 report of the Office of the United States Trade Representative (USTR) issued today sparked a quick outcry among health advocates over its seemingly more restrictive approach they say bullies other countries into unfairly promoting US pharmaceutical industry rights to an extent that would raise drug prices and limit accessibility. Continue reading -> USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> UAEM Students Launch Campaign To Drop Publicly Funded Patent Claim On Cancer Drug In India 16/03/2018 William New The Universities Allied for Essential Medicines (UAEM) this week launched a campaign to ask the University of California to drop its pursuit of a patent on the prostrate cancer drug Xtandi in India in order to make it affordable for patients. Xtandi sells at "exorbitant" rates in the United States, they said, a seeming violation of the licensing guidelines of the publicly funded University of California system which guarantees an "appropriate" return on taxpayer investments. Continue reading -> CARB-X Announces 2018 Round Of Funding For Antibacterial Research 23/02/2018 William New CARB-X , a global private-public partnership for research on antimicrobial resistance, this week announced its 2018 rounds of funding for research on "antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria." Continue reading -> “We Count On The US To Maintain Its Commitment” – Global Fund On US Budget Cut 22/02/2018 William New Some international organisations are having to gear up to address proposed cuts to their budgets announced this month by the United States, in many cases the major funder. Geneva-based health agencies this week responded that they are counting on the US not to make significant cuts. Continue reading -> Indian Pharma Industry Disputes US Industry IP Index 15/02/2018 William New The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving". Continue reading -> Posts navigation Older postsNewer posts
USTR Annual Special 301 Report Intensifies Action On China, Colombia, Canada 27/04/2018 William New The annual report of the Office of the United States Trade Representative (USTR) on the adequacy of trading partners’ protection of US intellectual property rights celebrated its 30th year this year with a sharper tone with China, in keeping with the Trump administration’s tough stance on the country. Also caught in the report are Colombia and Canada, which were downgraded to the “priority watch list.” Also, this year the report includes a special highlight on pharmaceuticals and medical devices. Continue reading -> UAEM Students Launch Campaign To Drop Publicly Funded Patent Claim On Cancer Drug In India 16/03/2018 William New The Universities Allied for Essential Medicines (UAEM) this week launched a campaign to ask the University of California to drop its pursuit of a patent on the prostrate cancer drug Xtandi in India in order to make it affordable for patients. Xtandi sells at "exorbitant" rates in the United States, they said, a seeming violation of the licensing guidelines of the publicly funded University of California system which guarantees an "appropriate" return on taxpayer investments. Continue reading -> CARB-X Announces 2018 Round Of Funding For Antibacterial Research 23/02/2018 William New CARB-X , a global private-public partnership for research on antimicrobial resistance, this week announced its 2018 rounds of funding for research on "antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria." Continue reading -> “We Count On The US To Maintain Its Commitment” – Global Fund On US Budget Cut 22/02/2018 William New Some international organisations are having to gear up to address proposed cuts to their budgets announced this month by the United States, in many cases the major funder. Geneva-based health agencies this week responded that they are counting on the US not to make significant cuts. Continue reading -> Indian Pharma Industry Disputes US Industry IP Index 15/02/2018 William New The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving". Continue reading -> Posts navigation Older postsNewer posts
UAEM Students Launch Campaign To Drop Publicly Funded Patent Claim On Cancer Drug In India 16/03/2018 William New The Universities Allied for Essential Medicines (UAEM) this week launched a campaign to ask the University of California to drop its pursuit of a patent on the prostrate cancer drug Xtandi in India in order to make it affordable for patients. Xtandi sells at "exorbitant" rates in the United States, they said, a seeming violation of the licensing guidelines of the publicly funded University of California system which guarantees an "appropriate" return on taxpayer investments. Continue reading -> CARB-X Announces 2018 Round Of Funding For Antibacterial Research 23/02/2018 William New CARB-X , a global private-public partnership for research on antimicrobial resistance, this week announced its 2018 rounds of funding for research on "antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria." Continue reading -> “We Count On The US To Maintain Its Commitment” – Global Fund On US Budget Cut 22/02/2018 William New Some international organisations are having to gear up to address proposed cuts to their budgets announced this month by the United States, in many cases the major funder. Geneva-based health agencies this week responded that they are counting on the US not to make significant cuts. Continue reading -> Indian Pharma Industry Disputes US Industry IP Index 15/02/2018 William New The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving". Continue reading -> Posts navigation Older postsNewer posts
CARB-X Announces 2018 Round Of Funding For Antibacterial Research 23/02/2018 William New CARB-X , a global private-public partnership for research on antimicrobial resistance, this week announced its 2018 rounds of funding for research on "antibiotics, vaccines, diagnostics, devices and other life-saving products to respond to the threat of drug-resistant bacteria." Continue reading -> “We Count On The US To Maintain Its Commitment” – Global Fund On US Budget Cut 22/02/2018 William New Some international organisations are having to gear up to address proposed cuts to their budgets announced this month by the United States, in many cases the major funder. Geneva-based health agencies this week responded that they are counting on the US not to make significant cuts. Continue reading -> Indian Pharma Industry Disputes US Industry IP Index 15/02/2018 William New The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving". Continue reading -> Posts navigation Older postsNewer posts
“We Count On The US To Maintain Its Commitment” – Global Fund On US Budget Cut 22/02/2018 William New Some international organisations are having to gear up to address proposed cuts to their budgets announced this month by the United States, in many cases the major funder. Geneva-based health agencies this week responded that they are counting on the US not to make significant cuts. Continue reading -> Indian Pharma Industry Disputes US Industry IP Index 15/02/2018 William New The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving". Continue reading -> Posts navigation Older postsNewer posts
Indian Pharma Industry Disputes US Industry IP Index 15/02/2018 William New The United States Chamber of Commerce industry group recently issued its annual global IP index, analysing intellectual property protection in 50 countries, as a prelude to the annual US government list of countries seen as not adequately protection US companies' IP rights. Now an Indian industry group has issued a counter-statement to the Chamber index, calling it a "tirade" and "self-serving". Continue reading -> Posts navigation Older postsNewer posts